-Economic and Political Weekly Since independence, India's national health policies have been aspirational but the end results have been limited. The National Health Policy 2015, which is in the process of being finalised, should, in place of the earlier "broadband" approach, adopt a "narrow focus" on primary healthcare through the National Rural Health Mission. The latter has focused on primary healthcare and has shown visible results. A slew of suggestions as...
More »SEARCH RESULT
Total Matching Records found : 382
This time we should get health right -Santosh Mehrotra
-The Hindustan Times The drafting of the National Health Policy (NHP) 2015 is an extremely welcome development. The government's decision to announce Health as a Right is a huge advance. Public health spending as a share of GDP barely rose from 0.9 to 1.1% under the previous government. Governments in rich countries have been spending 5% of GDP on health for decades. Why should we welcome the NHP 2015? Countries with...
More »Indian drug cos worried about patent regime changes -PT Jyothi Datta
-The Hindu Business Line Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on...
More »Govt to sell 504 drugs under 'Jan Aushadhi' -Sushmi Dey
-The Times of India NEW DELHI: From July 1, you can walk up to a chemist and ask for a 'Jan Aushadhi' brand for your medicine, with the government set to launch its own brand to sell low cost generic medicines. The Centre will procure medicines in bulk from public as well as private drug manufacturing firms and rebrand them under 'Jan Aushadhi'. These will be sold in the retail market at...
More »More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta
-The Hindu Business Line Mumbai: A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month. Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application...
More »
